Volume 5.01 | Jan 10

Mammary Cell News 5.01 January 10, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles to Overcome Drug Resistance in Breast Cancer In Vitro and In Vivo
Scientists used a multifunctional mesoporous silica nanoparticle carrier to overcome doxorubicin (Dox) resistance in a multidrug resistant human breast cancer xenograft by codelivering Dox and siRNA that targets the P-glycoprotein drug exporter. [ACS Nano] Abstract

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence
Researchers showed that the expression in different breast epithelial cell lines of p95HER2, a constitutively active fragment of the tyrosine kinase receptor HER2, results in either increased proliferation or senescence. [Cancer Res] Abstract

Oral Vaccination with Adeno-Associated Virus Vectors Expressing the Neu Oncogene Inhibits the Growth of Murine Breast Cancer
The authors examined the activity of an oral and intramuscular antitumor vaccination using adeno-associated viruses serotypes 5 and 6 expressing a truncated neu oncogene in a neu-positive murine TUBO breast cancer model. [Mol Ther] Abstract

The Oncoprotein HBXIP Activates Transcriptional Coregulatory Protein LMO4 via Sp1 to Promote Proliferation of Breast Cancer Cells
Researchers report that hepatitis B X-interacting protein (HBXIP) activates LIM-only protein 4 (LMO4), a transcriptional coregulatory protein, in promotion of cell proliferation. They observed that the mRNA expression levels of HBXIP were positively associated with those of LMO4 in clinical breast cancer tissues. [Carcinogenesis] Abstract | Full Article

Hypoxia Stimulates Migration of Breast Cancer Cells via the PERK/ATF4/LAMP3-Arm of the Unfolded Protein Response
The PKR-like ER kinase (PERK)/activating transcription factor 4 (ATF4)-arm of the unfolded protein response (UPR) induces expression of Lysosomal-Associated Membrane Protein 3 (LAMP3), a factor that has been linked to metastasis and poor prognosis in solid tumors. The role of UPR-induced LAMP3 in hypoxia-mediated migration of breast cancer cells was examined. [Breast Cancer Res] Abstract | Full Article

Decreased Expression of ADAMTS-1 in Human Breast Tumors Stimulates Migration and Invasion
The authors investigated mRNA and protein levels of ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin motifs) in normal and neoplastic tissues using qPCR, immunohistochemistry and immunoblot analyses, and they addressed the role of ADAMTS-1 in regulating migration, invasion and invadopodia formation in breast tumor cell lines. [Mol Cancer]
Abstract | Full Article

Regulation of Epithelial Cell Turnover and Macrophage Phenotype by Epithelial Cell-Derived Transforming Growth Factor Beta1 in the Mammary Gland
In the breast, the mammary epithelium is the primary source of transforming growth factor beta1 (TGFB1) and increased expression is associated with increased breast cancer risk. The authors investigated the roles of epithelial cell-derived TGFB1 in regulation of epithelial cell activity and macrophage phenotype in the mammary gland. [Cytokine] Abstract

miR-199b-5p Targets HER2 in Breast Cancer Cells
Scientists found microRNA(miR)-199b-5p inhibited HER2 expression by direct targeting its 3′-untranslated region in breast cancer cells. In addition, miR-199b-5p inhibited HER2 downstream signaling by ERK1/2 and AKT pathways in breast cancer cells. [J Cell Biochem] Abstract

CLINICAL RESEARCH

Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared with Concurrent Doxorubicin and Docetaxel in Node-Positive Breast Cancer-8-Year Results of the Breast International Group 02-98 Phase III Trial
In women with node-positive breast cancer, the Breast International Group 02-98 tested the incorporation of docetaxel into doxorubicin-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival with docetaxel. The authors present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes. [Ann Oncol] Abstract

Clinical Pathological Characteristics and Prognostic Analysis of 1,013 Breast Cancer Patients with Diabetes
Researchers investigated the clinical, pathological, and prognostic characteristics of breast cancer patients with diabetes. The study included 1,013 breast cancer patients with diabetes and 4,621 breast cancer patients without diabetes. [Breast Cancer Res Treat] Abstract

[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.

REVIEWS
Role of MicroRNAs in Breast Cancer
Substantial research on microRNAs (miRNAs) highlights the involvement of these tiny RNAs in the etiopathogenesis of a variety of human diseases such as cancer, neuro-degenerative disorders, diabetes, cardiac hypertrophy and respiratory diseases. The authors update on recent advances of the emerging role of miRNAs in breast cancer and their clinical implications. [Cancer Biol TherFull Article
INDUSTRY NEWS

Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/Neu Antigens
TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. [TapImunne Inc.] Press Release

EntreMed Files New Drug Clinical Trial Application for ENMD-2076 with China SFDA to Advance Global Development Strategy
EntreMed, Inc. announced that EntreMed has submitted a new drug clinical trial application with China’s State Food and Drug Administration (SFDA) for its proprietary drug candidate, ENMD-2076, to conduct global clinical trials in triple-negative breast cancer patients. [EntreMed, Inc.] Press Release

Kinex Pharmaceuticals and Hanmi Pharmaceutical Announce First Patient Has Been Enrolled in Phase Ib/IIa Clinical Trial in Korea
Kinex Pharmaceuticals and Hanmi Pharmaceutical announced that the first patient has been enrolled in Hanmi’s Phase Ib/IIa clinical trial in Korea. Kinex’s dual Src/pretubulin Inhibitor, KX01, is being combined with intravenous paclitaxel to treat solid tumor patients in Phase Ib and then gastric and breast cancer patients in Phase IIa. [Kinex Pharmaceuticals] Press Release

POLICY NEWS

Stem Cell Lawsuit Finally Over
The Supreme Court rejected a request to ban U.S.-funded research on human embryonic stem cells (hESCs). The decision brings to an end a long legal battle that has cast a shadow over hESC studies for over three years. [Supreme Court, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW 6th Oncology Biomarkers
March 20-22, 2013
San Francisco, United States

Visit
our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Assistant Professor – Breast Cancer (Cedars-Sinai Medical Center)

Principal Investigator – Cancer Research (Institut de Recherches Cliniques de Montréal)

Postdoctoral Position – Genetic Biomarkers in Breast Cancer (Rush University Medical Center)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Postdoctoral Position/PhD Student – Resistance to Anti-Cancer Drug Therapy (The Netherlands Cancer Institute)

Laboratory Technician/Manager Position – MicroRNA Cancer Biology (Thomas Jefferson University)

Postdoctoral Position –  Impact of Ubiquitin-Proteasome Pathway in Genome Stability and Breast Cancer (University of Pittsburgh)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us